Press Releases

 
Press Releases
  Date Title and Summary View
Sep 1, 2016
NOVATO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Baird 2016 Global Healthc...
Aug 23, 2016
NOVATO, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced ost...
Aug 9, 2016
NOVATO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences: Shalini Sharp, the company's Chief Financial...
Aug 8, 2016
NOVATO, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2016. "We are advancing and building ...
Aug 1, 2016
NOVATO, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, August 8, 2016 at 5pm ET to discuss second quarter 2016 financial results and...
Jul 28, 2016
NOVATO, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the  Phase 3 study of KRN23 for the treatment of adults with X...
Jul 27, 2016
NOVATO, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the  Phase 3 study of aceneuramic acid extended release (Ac...
Jul 14, 2016
Study meets primary endpoint of reduction in urinary GAG excretion and provides evidence of clinical improvement Company to host conference call today at 5pm ET to discuss results NOVATO, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a b...
Jul 13, 2016
NOVATO, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that data from the pivotal Phase 3 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigation...
Jun 28, 2016
NOVATO, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for KRN23 for the tre...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase